Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for Patients With Unresectable Malignant Pleural Mesothelioma

Inclusion Criteria

• •Pathologically confirmed diagnosis of malignant pleural mesothelioma at MSKCC
• •No plans for surgical resection
• •Stage T1-4, N0-3, M0
• •No prior radiation therapy to the chest, breast or supraclavicular fossa that would limit radiation delivery to the full prescription dose
• •Prior chemotherapy regimens ≤1
• •Age ≥18 years
• •Karnofsky performance status ≥ 80%
• •Pulmonary function tests as follows: DLCO\>50% predicted
• •Adequate hematologic, hepatic, and renal function as indicated by the following laboratory values
• •* Absolute neutrophil count ≥ 1,500/mcL
• •* Platelets ≥ 100,000/mcL
• •* Calculated creatinine clearance (CrCl) ≥ 45mL/min (using Cockcroft \& Gault method)
• •* Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN) (unless known Gilbert's disease)
• •* AST (SGOT) and ALT (SGPT) ≤ 3.0 x ULN